Abstract
In recent years, it has been noted that the combination of radiation and immunotherapy is more benefitial than both modalities used separately. The interactions between immune checkpoint inhibitors and high-dose radiotherapy are curently an important topic of ongoing scientific trials. This review highlights some of the presented papers during the ESTRO 37 congress in 2018.
References
Rodolfo Chicas-Sett, Ignacio Morales-Orue, Delvys Rodriguez-Abreu, Pedro Lara-Jimenez. Clin Transl Radiat Oncol. 2018 Feb; 9: 5–11. 10.1016/j.ctro.2017.12.004
Sundahl N. et al. J Transl Med. 2017 Jun 29;15(1):150. doi: 10.1186/s12967-017-1251-3
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) https://clinicaltrials.gov/ct2/show/NCT02853305
Xuanwei Zhang, MSc and Gabriele Niedermann, MD. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of
the Tumor-Specific T-Cell Response. Int. Journal of Radiation Oncology
'End of an Era' for Chemo in Non-Small Cell Lung Cancer - Medscape - Jun 03, 2018.